Xu Guo

Xu Guo

Auto-generated profile, based on publicly available information

Xu Guo

The Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CZChao Zhang
Chao Zhang
MMMin Mao
Min Mao
XGXu Guo
Xu Guo
PCPing Cui
Ping Cui
LZLianmin Zhang
Lianmin Zhang
GWGuowen Wang
Guowen Wang
The purpose of the present study was to characterize the prevalence, associated factors, and to construct a nomogram for predicting bone metastasis (BM) with different histological types of lung cancer. This study was a descriptive study that basing on the invasive lung cancer patients diagnosed between 2010 and 2014 in Surveillance, Epidemiology, and End Results program. A total of 125,652 adult patients were retrieved. Logistic regression analysis was conducted to investigate homogeneous and heterogeneous factors for BM occurrence. Nomogram was constructed to predict the risk for developing BM and the performance was evaluated by the receiver operating characteristics curve (ROC) and the calibration curve. The overall survival of the patients with BM was analyzed using the Kaplan–Meier method and the survival differences were tested by the log-rank test. A total of 25,645 (20.9%) were reported to have BM, and the prevalence in adenocarcinoma, squamous cell carcinoma, small cell lung cancer (SCLC), large cell lung cancer (LCLC), and non-small cell lung cancer/not otherwise specified lung cancer (NSCLC/NOS) were 24.4, 12.5, 24.7, 19.5 and 19.4%, respectively, with significant difference (P < 0.001). Male gender, more metastatic sites and lymphatic metastasis were positively associated with BM in all lung cancer subtypes. Larger tumor size was positively associated with BM in all the lung cancer subtypes except for NSCLC/NOS. Poorly differentiated histology was positively associated with adenocarcinoma, squamous cell carcinoma and NSCLC/NOS. The calibration curve and ROC curve exhibited good performance for predicting BM. The median survival of the bone metastatic lung cancer patients was 4.00 (95%CI: 3.89–4.11) months. With the increased number of the other metastatic sites (brain, lung and liver metastasis), the survival significantly decreased (p < 0.001). Different lung cancer histological subtypes exhibited distinct prevalence and homogeneity and heterogeneity associated factors for BM. The nomogram has good calibration and discrimination for predicting BM of lung cancer.

9 January 2026 in Medicine
Verified
Journal Article
Open access
WZWeiqin Zhao
Weiqin Zhao
YLYile Lin
Yile Lin
HWHaixiao Wu
Haixiao Wu
JWJun Wang
Jun Wang
VCVladimir P. Chekhonin
Vladimir P. Chekhonin
CZChao Zhang
Chao Zhang
This study aims to investigate the incidence of and factors associated with bone metastasis (BM) in patients with lung cancer and provide guidance for the screening of BM in patients with lung cancer. Lung cancer patients who were treated at the Tianjin Medical University Cancer Institute and Hospital between 2009 and 2018 were retrospectively reviewed. Patients with synchronous BM were obtained to investigate the risk factors for BM development. Both demographic and clinical characteristics were included. Univariate and multivariate logistic regression analyses were performed to identify risk factors. A further scoring system was established to classify patients into 3 different risk groups. Five significant risk factors were identified, namely, male sex, Karnofsky score of 50 to 70, multiple primary lesions, lymph node metastasis, and adenocarcinoma. The total score was generated by the integration of the score based on each individual factor. The incidence of BM among patients with lung cancer with a total score ≥ 7 was 46.73%, the incidence among patients with a total score ≤ 4 was 16.59%, and the incidence of BM in patients with total scores between 5 and 6 was 34.23%. This scoring system can predict the risk of BM in patients with lung cancer and can guide the performance of BM screening.